Researchers investigated non-melanoma skin cancer prevalence among sexual orientation identities by race/ethnicity and gender.

Researchers reported on patient acceptance of an e-consent tool for asynchronous delivery of study information and for receiving consent from patients.

Median progression-free survival was 22 months, overall survival was 152 months among patients with newly diagnosed MM.

Among a heavily pretreated, older adult population of patients with relapsed/refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML), revumenib was associated with a clinically ...

Medical professionals who use social media to educate the public on health-related topics have grown in prominence.

Researchers assessed variations in patterns of care and time to initial treatment for women diagnosed with breast, cervical, or ovarian cancer in various countries.

These findings indicate serial ctDNA monitoring could identify patients with muscle-invasive bladder cancer who benefit from adjuvant atezolizumab, while sparing patients who are persistently negative ...

Thrombotic risk with PICCs matched that of totally implantable venous access devices, showing comparable long-term safety.

PRRT retreatment may be well tolerated and confer a survival benefit in patients with well-differentiated, metastatic neuroendocrine tumors, a study suggests.

Mindfulness-based interventions beneficial for nurses, midwives, while professional coaching effective for physicians.

POTOMAC supports 1 year of durvalumab with BCG induction and maintenance therapy as a potential new treatment in BCG-naïve, high-risk NMIBC,” said Maria De Santis, MD.

Abemaciclib is the first CDK4/6 inhibitor to produce a significant overall survival benefit in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer, ...